The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The BEQVEZ gene therapy inserts a working copy of the Factor IX (FIX) gene that codes for a high-activity FIX variant.
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an ...
The FDA approved its first gene therapy companion diagnostic test last June, developed through a collaboration between ARUP ...
Pfizer (PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with ...
Pfizer's groundbreaking $3.5 million gene therapy for Hemophilia B just got FDA approval. Here’s what it means for patients ...
In announcing its approval on Friday, the Food and Drug Administration said it had approved Pfizer’s treatment for a rare ...
Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene ...